Adagene Inc.

Contributing Author

Recent Articles by Adagene Inc.

Oct-31	Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer ADAG GlobeNewswire
Sep-16	Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate ADAG GlobeNewswire
Sep-05	Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China ADAG GlobeNewswire
Sep-03	Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor ADAG GlobeNewswire
Aug-26	Adagene to Participate in Two Investor Conferences in September ADAG GlobeNewswire
Aug-12	Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates ADAG GlobeNewswire
Jul-15	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA ADAG GlobeNewswire
Jul-08	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate ADAG GlobeNewswire
Jul-01	Adagene announces up to $25 million strategic investment from Sanofi ADAG GlobeNewswire
May-27	Adagene to Present at Jefferies Global Healthcare Conference 2025 ADAG GlobeNewswire
May-22	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting ADAG GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.